Form 4: Lynx1 Capital Boosts Stake in Neuphoria Therapeutics

Lynx1 Capital Management LP and Weston Nichols acquired 639,110 shares of Neuphoria Therapeutics Inc. common stock for approximately $3.28 million.

Summary

• Lynx1 Capital Management LP and Weston Nichols, identified as a 10% owner and director of Neuphoria Therapeutics Inc. (NEUP), reported an acquisition of common stock.
• The transaction involved the purchase of 639,110 shares of common stock, with a par value of $0.00001 per share.
• The shares were acquired on October 21, 2025, at a weighted average price of $5.137 per share.
• The purchase price for these shares ranged from $4.96 to $5.20 per share.
• Following this transaction, the reporting persons indirectly beneficially own a total of 875,328 shares of Neuphoria Therapeutics Inc. common stock.
• The securities are held directly by Lynx1 Master Fund LP, for which Lynx1 Capital Management LP serves as investment manager, and Weston Nichols is the sole member of its general partner.

Sentiment

Score: 8

Explanation: The significant purchase of common stock by a 10% owner and director, Lynx1 Capital Management LP and Weston Nichols, indicates strong confidence in Neuphoria Therapeutics Inc.'s future. This type of insider activity is often viewed favorably by the market.

Positives

• Significant insider buying by a 10% owner and director, indicating strong confidence in the company's future prospects.
• The acquisition of 639,110 shares represents a substantial increase in the reporting persons' beneficial ownership.
• The total value of the acquired shares is approximately $3,284,000 (639,110 shares * $5.137/share), demonstrating a material investment.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports a change in beneficial ownership.

Management Comments

• The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.96 to $5.20 inclusive.
• The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
• Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.

Industry Context

Insider buying, particularly by significant shareholders and directors, is often interpreted by the market as a strong signal of confidence in a company's future prospects. This transaction by Lynx1 Capital Management LP and Weston Nichols suggests a belief that Neuphoria Therapeutics Inc.'s stock is undervalued or poised for growth, potentially influencing other investors' perceptions and decisions within the biotechnology or pharmaceutical industry.

Related Party Transactions

• The acquisition of 639,110 shares of common stock by Lynx1 Capital Management LP and Weston Nichols, who are a 10% owner and director, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May view the significant insider purchase as a positive signal, potentially increasing confidence in the company's stock and future performance.
• Employees: No direct impact mentioned, but increased investor confidence could indirectly benefit the company's stability and growth prospects.
• Customers/Suppliers/Creditors: No direct impact mentioned in this filing.

Key Dates

Recommendation

The substantial purchase of Neuphoria Therapeutics Inc. common stock by a 10% owner and director, Lynx1 Capital Management LP and Weston Nichols, signals strong insider confidence. Such significant insider buying often precedes positive company developments or indicates a belief that the stock is undervalued, making it a compelling "buy" signal for seasoned investors.

Keywords

Neuphoria Therapeutics, NEUP, Lynx1 Capital Management, Weston Nichols, insider buying, stock purchase, beneficial ownership, Form 4, equity acquisition, investment manager, director, 10% owner